-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on ResMed, Raises Price Target to $290

Benzinga·08/01/2025 16:38:15
Listen to the news
Mizuho analyst Anthony Petrone maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $270 to $290.